March 4, 2019
Verona Pharma to start second part of Phase 2 trial of COPD inhibitor ensifentrine
Verona Pharma is aiming to start second part of Phase 2 trial to test ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment, it said after announcing positive data from part one of the trial.